Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer

Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be presented as an oral poster at the 20th Asia-Pacific Prostate Cancer Conference, which will be held August 23-26 in Melbourne, Australia. The data will be presented in an oral, moderated poster session… Continue reading Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer

Canada allows combination of Janssen’s Zytiga with ADT in to treat certain prostate cancer (mHSPC)

Johnson & Johnson’s Janssen has welcomed the news from Health Canada as it got approval to use Zytiga combined with prednisone and androgen deprivation therapy (ADT) for newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who may have received up to three months of prior ADT.